Kombiglyze XR gets green light from KFDA
Published: 2012-04-16 06:58:00
Updated: 2012-04-16 06:58:00
The Korea Food and Drug Administration said Thursday it approved AstraZeneca and Bristol-Myers Squibb’s combo drug Kombiglyze XR (saxagliptin and metformin HCl extended-release), five months after initial approval of Onglyza.
The once-daily Kombiglyze is a dipeptidyl peptidase-4 (DPP4) inhibit...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
